MET and cancer: ARGX-111 is an afucosylated IgG1 antibody that competitively binds c-MET, inhibits c-MET activity, and downregulates c-MET expression on the cell surface.1234 A clinical phase I trial of ARGX-111 in patients with advanced cancer overexpressing c-MET has been completed (NCT02055066).